Promis Neurosciences PMN
11.27
(0.30)
(2.59%)
as of 25 Sep
- Market cap
- $103.8M
- P/E
- 0.0×
Follow PMN
Insider Buys
alert about insiders buying in the last 12 month
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
P/S ratio |
0.00 | 0.00 | 159,800.00 | 30,756.82 | 10,407.27 | — | — | — | — | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
P/Operating CF |
0.00 | (29.83) | (21.15) | (32.52) | (33.50) | — | — | — | — | — |
P/B ratio |
0.00 | 27.90 | 53.74 | 112.78 | 0.00 | — | — | — | — | — |
Price to Tangible BV |
0.00 | 29.07 | 56.42 | 128.35 | 0.00 | — | — | — | — | — |
EV/Sales |
0.00 | 0.00 | 153,547.67 | 29,589.73 | 10,043.86 | — | — | — | — | — |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
EV/Operating CF |
0.00 | (7.20) | (6.91) | (7.09) | (6.80) | — | — | — | — | — |
EV/FCF |
0.00 | (7.20) | (6.91) | (7.09) | (6.80) | — | — | — | — | — |
Quick Ratio |
0.89 | 2.79 | 1.37 | 1.06 | 0.46 | 18.31 | 0.93 | 1.35 | 6.01 | 0.59 |
Current Ratio |
1.00 | 3.31 | 1.61 | 1.21 | 0.52 | 19.07 | 1.08 | 1.46 | 8.52 | 0.88 |
Net Debt/EBITDA |
0.22 | 0.29 | 0.24 | 0.23 | 0.19 | 1.59 | 0.25 | 0.89 | 0.79 | 0.15 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 22.01% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.69 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.74 | 0.95 | 0.85 | 0.82 | 0.77 | 0.95 | 0.94 | 0.82 | (9.78) | 0.71 |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | (6.93) | 2.02 | (0.18) | 0.00 | — | — |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 0.00% | (751.91%) | (756.07%) | (935.12%) | 1,844.24% | (399.46%) | (837.71%) | (1,098.52%) | 27.46% | (521.61%) | |
| 0.00% | (386.10%) | (395.87%) | (289.47%) | (325.59%) | (104.26%) | (146.42%) | (128.63%) | 17.08% | (282.76%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (332.40%) | 0.00% |
Return on Tangible Assets |
(326,150.00%) | (409.00%) | (923.14%) | (2,114.49%) | 533.91% | (58.31%) | (3,680.18%) | (309.46%) | 16.65% | 3,230.78% |
Average Days of Receivables |
6,387.50 | 1,709.74 | 38,507.50 | 22,670.56 | 8,310.77 | 0.00 | 0.00 | — | — | — |
Research and Development Expense of Revenue |
70,440.00% | 40,207.89% | 1,429,125.00% | 396,500.00% | 182,784.62% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
59,520.00% | 20,923.68% | 531,950.00% | 222,911.11% | 142,469.23% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.07 | 0.03 | 0.02 | 0.02 | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
21,585.00% | 7,047.37% | 207,325.00% | 54,211.11% | 15,038.46% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
0.00 | 0.03 | 0.02 | 0.01 | (0.04) | — | — | — | — | — |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 44.51 | — | — | — | — | — |
Earnings Yield |
(14.08%) | (14.08%) | (16.30%) | (16.47%) | (18.46%) | — | — | — | — | — |
Free Cash Flow Yield |
0.00% | (13.32%) | (13.91%) | (13.56%) | (14.20%) | — | — | — | — | — |
Revenue per Share |
0.02 | 0.06 | 0.00 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(16.93) | (31.97) | (41.73) | (26.45) | (17.04) | (40.21) | (56.76) | (22.05) | (26.21) | (16.00) |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | (0.43) | 0.40 | (0.01) | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
(16.93) | (31.97) | (41.73) | (26.45) | (17.46) | (39.81) | (56.77) | (22.05) | (26.21) | (16.00) |
Cash per Share |
5.01 | 9.71 | 11.74 | 7.40 | 4.19 | 73.37 | 19.68 | 25.69 | 12.85 | 3.50 |
Shareholders Equity per Share |
0.46 | 8.60 | 5.58 | 1.73 | (3.97) | 24.46 | (4.49) | 7.63 | 15.90 | (0.72) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.46 | 8.60 | 5.58 | 1.73 | (3.97) | 24.46 | (4.49) | 7.63 | 15.90 | (0.72) |
Free Cash Flow |
(1.92) | (4.40) | (6.67) | (4.59) | (3.33) | (9.21) | (17.04) | (10.84) | (27.18) | (28.12) |
Working Capital |
0.00 | 1.13 | 0.85 | 0.26 | (0.87) | 16.79 | 0.49 | 4.27 | 16.69 | (1.23) |
Capital Expenditures |
— | — | — | — | (0.08) | 0.09 | 0.00 | — | — | — |
Net Current Asset Value |
0.00 | 1.13 | 0.85 | 0.26 | (0.87) | 5.63 | (1.37) | 3.75 | 16.49 | (1.26) |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 62.38 | 0.00 | 0.00 | — | — | — |
Net Profit Margin |
(130,460.00%) | (61,102.63%) | (1,960,975.00%) | (619,311.11%) | (325,153.85%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
3.57 | 3.40 | 3.40 | 0.00 | 0.16 | 9.74 | 37.33 | 0.00 | — | — |
Cash ROIC |
(309.43%) | (174.65%) | (240.99%) | (289.76%) | (8,090.51%) | (35.08%) | (373.64%) | (66.19%) | (91.18%) | (574.82%) |
Accounts Receivable Turnover |
0.00 | 0.22 | 0.01 | 0.02 | 0.03 | 0.00 | 0.00 | — | — | — |
Accounts Payable Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | — | — | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | — | — | 0.00 | 0.00 | — | — | — |
Average Receivables |
— | 0.04 | 0.04 | 0.05 | 0.04 | 0.03 | 0.05 | — | — | — |
Average Payables |
— | 0.39 | 0.38 | 0.83 | 0.76 | 0.41 | 1.69 | 5.41 | 4.79 | 2.14 |
Average Assets |
— | 1.20 | 1.98 | 1.93 | 1.30 | 9.39 | 12.34 | 10.27 | 16.27 | 14.05 |
Average Common Equity |
— | 0.62 | 1.04 | 0.60 | (0.23) | 2.45 | 2.16 | 1.20 | 10.12 | 7.61 |
Columns are period end dates